Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medicine to alleviate Huntington's?

14.06.2007
Huntington's disease is a hereditary disorder that primarily affects the brain, leading to death within just over a decade. There is no treatment for the disease at present, but researchers at Lund University in Sweden believe that a medicine used for Alzheimer's disease could alleviate some of the symptoms.

Huntington's disease is caused by a mutation of a gene that the produces the Huntington protein. This protein influences a number of processes in the cells of the brain. The disorder first appears as symptoms like personality changes and depression, followed by dementia, weight loss, and jerky movements (which is why it used to be called Huntington's chorea, chorea - from the greek word for dance).

A research team at Lund, headed by Professor Patrik Brundin, has long been studying Huntington's disease in order to elucidate its complex mechanisms. Ruben Smith, a doctoral student in the group, supervised by Associate Professor Jia-Yi Li, will soon be defending a dissertation in which he studied a certain type of nerve cells called cholinergic neurons. These nerve cells release acetylcholine, one of the body's most common and important signal substances.

"It was previously believed that these nerve cells were not affected by Huntington's, but we show that their function is probably seriously impaired by the disorder," he says.

The discovery opens the possibility of counteracting the disease by reinforcing the production of acetylcholine in the cholinergic nerve cells. Substances that have this effect already exist: they are used to treat Alzheimer's disease, in which cholinergic neurons are also damaged.

"A couple of studies have been done with this type of medication for Huntington's patients, but they have involved a small number of patients and a short time period. We think our results justify studies on a larger scale. After all, the drug is already approved for use," says Ruben Smith.

If the medication has an effect, it will probably impact memory and thinking primarily, not motor symptoms. The medicine would not halt the course of the disease: it would merely alleviate it. But considering the fact that there is no treatment whatsoever today, this would be a step forward.

The dissertation is titled Communication Breakdown - Synaptic Dysfunction in Huntington's Disease. It will be defended on June 16. A summary is available at http://theses.lub.lu.se/postgrad/. Enter Huntington's in the search box.

Ruben Smith can be reached at phone: +46 (0)46-2229827; cell phone: +46 (0)702-765214; e-mail: ruben.smith@med.lu.se

Ingela Björck | idw
Further information:
http://theses.lub.lu.se/postgrad/

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Gran Chaco: Biodiversity at High Risk

17.01.2018 | Ecology, The Environment and Conservation

Only an atom thick: Physicists succeed in measuring mechanical properties of 2D monolayer materials

17.01.2018 | Physics and Astronomy

Fraunhofer HHI receives AIS Technology Innovation Award 2018 for 3D Human Body Reconstruction

17.01.2018 | Awards Funding

VideoLinks
B2B-VideoLinks
More VideoLinks >>>